Oral estroprogestin: An alternative low cost therapy for women with postoperative persistent acromegaly?

Pituitary

Volumn 13, Issue 4, 2010, Pages 311-314

  Vallette, Sophie ^a   Serri, Omar ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Acromegaly; Estroprogestin; GH; IGF 1; Octreotide LAR

Indexed keywords

ETHINYLESTRADIOL PLUS LEVONORGESTREL; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OCTREOTIDE; SOMATOMEDIN C; TRIACYLGLYCEROL;

ACROMEGALY; ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG ADMINISTRATION ROUTE; DRUG COST; DRUG EFFICACY; DRUG INTERACTION; DRUG POTENTIATION; DRUG TOLERABILITY; ENDOCRINE SURGERY; ESTROGEN THERAPY; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE BLOOD LEVEL; HUMAN; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PILOT STUDY; POSTOPERATIVE PERSISTENT ACROMEGALY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; TREATMENT DURATION; TREATMENT FAILURE; TUMOR GROWTH;

ACROMEGALY; ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD GLUCOSE; DRUG COMBINATIONS; DRUG THERAPY; ETHINYL ESTRADIOL; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LIPIDS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NORPREGNENES; OCTREOTIDE; TREATMENT OUTCOME;

EID: 78049311226     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-010-0236-5     Document Type: Article

References (17)

1. IM Holdaway MJ Bolland GD Gamble 2008 A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly Eur J Endocrinol 159 2 89 95 1:CAS:528:DC%2BD1cXhtVOhs7vL 10.1530/EJE-08-0267 18524797
2. S Melmed A Colao A Barkan, et al. 2009 Guidelines for acromegaly management: an update J Clin Endocrinol Metab 94 5 1509 1517 1:CAS:528:DC%2BD1MXlvVCqsbk%3D 10.1210/jc.2008-2421 19208732
3. P Nomikos M Buchfelder R Fahlbusch 2005 The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure' Eur J Endocrinol 152 3 379 387 1:CAS:528:DC%2BD2MXivVClu7g%3D 10.1530/eje.1.01863 15757854 (Pubitemid 40439490)
4. S Melmed R Sternberg D Cook, et al. 2005 A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly J Clin Endocrinol Metab 90 7 4405 4410 1:CAS:528:DC%2BD2MXmtlChs7k%3D 10.1210/jc.2004-2466 15827109 (Pubitemid 41058228)
5. S Melmed 2006 Medical progress: acromegaly N Engl J Med 355 24 2558 2573 1:CAS:528:DC%2BD28XhtlWqsbzK 10.1056/NEJMra062453 17167139 (Pubitemid 44917504)
6. S Vallette O Serri 2008 Octreotide LAR for the treatment of acromegaly Expert Opin Drug Metab Toxicol 4 6 783 793 1:CAS:528:DC%2BD1cXos1Cgsb4%3D 10.1517/17425255.4.6.783 18611118 (Pubitemid 352003200)
7. R Abs J Verhelst D Maiter, et al. 1998 Cabergoline in the treatment of acromegaly: a study in 64 patients J Clin Endocrinol Metab 83 2 374 378 1:CAS:528:DyaK1cXhtVSnt7Y%3D 10.1210/jc.83.2.374 9467544 (Pubitemid 28496509)
8. R Cozzi R Attanasio S Lodrini G Lasio 2004 Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status Clin Endocrinol (Oxf) 61 2 209 215 1:CAS:528:DC%2BD2cXnslWltrc%3D 10.1111/j.1365-2265.2004.02082.x (Pubitemid 39093116)
9. PJ Trainer WM Drake L Katznelson, et al. 2000 Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant N Engl J Med 342 16 1171 1177 1:CAS:528:DC%2BD3cXjtVOkur4%3D 10.1056/NEJM200004203421604 10770982 (Pubitemid 30211048)
10. EP Mccullagh JC Beck CA Schaffenburg 1955 Control of diabetes and other features of acromegaly following treatment with estrogens Diabetes 4 1 13 23 1:STN:280:DyaG2M%2FmslahtQ%3D%3D 14365546
11. GJ Hamwi TG Skillman KC Tufts Jr 1960 Acromegaly Am J Med 29 690 699 1:STN:280:DyaF3c%2FjtVKkuw%3D%3D 10.1016/0002-9343(60)90101-7 13711140
12. DR Clemmons LE Underwood EC Ridgway B Kliman RN Kjellberg JJ Van Wyk 1980 Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status Am J Med 69 4 571 575 1:STN:280: DyaL3M%2Fjs1ygsQ%3D%3D 10.1016/0002-9343(80)90470-2 7424946 (Pubitemid 10018713)
13. R Cozzi M Barausse S Lodrini G Lasio R Attanasio 2003 Estroprogestinic pill normalizes IGF-I levels in acromegalic women J Endocrinol Invest 26 4 347 352 1:CAS:528:DC%2BD3sXmt1Wntrw%3D 12841543 (Pubitemid 36763696)
14. KC Leung G Johannsson GM Leong KK Ho 2004 Estrogen regulation of growth hormone action Endocr Rev 25 5 693 721 1:CAS:528:DC%2BD2cXhtVSjtrnN 10.1210/er.2003-0035 15466938 (Pubitemid 39366048)
15. N Panay 2009 Estrogen dose: the cardiovascular impact Climacteric 12 Suppl 1 91 95 1:CAS:528:DC%2BD1MXhsFOqsL7J 10.1080/13697130903008288 19811250
16. JC Stevenson HN Hodis JH Pickar RA Lobo 2009 Coronary heart disease and menopause management: the swinging pendulum of HRT Atherosclerosis 207 2 336 340 1:CAS:528:DC%2BD1MXhsFSgs7bP 10.1016/j.atherosclerosis.2009.05.033 19560146
17. H Lyytinen E Pukkala O Ylikorkala 2009 Breast cancer risk in postmenopausal women using estradiol-progestogen therapy Obstet Gynecol 113 1 65 73 19104361